Search
Prothena Corporation PLC
PRTAAdd to Watchlist
8.930USD
+0.440+5.18%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
480.73MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Prothena Corporation PLC is 6.67, ranking 327 out of 389 in the Biotechnology & Medical Research industry. The average price target is 18.50, with a high of 36.00 and a low of 8.00.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+139.64%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Prothena Corporation PLC
PRTA
6
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Prothena Corporation PLC's expected revenue for the next quarter?
Prothena Corporation PLC's expected revenue is 43.09M.
What is Prothena Corporation PLC's price target?
Analysts forecast that Prothena Corporation PLC's price target is USD 18.50, with the highest forecast at USD 36.00 and the lowest forecast at USD 8.00.
How have Prothena Corporation PLCPRTA's recent earnings per share performed?
The market expectation was USD 0.61, while Prothena Corporation PLCPRTA's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for Prothena Corporation PLC?
Based on the ratings of Prothena Corporation PLC's stock from 6 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
